Although researchers did not directly compare both drugs, the findings could be especially relevant for women who have difficulty tolerating existing medications such as tamoxifen
About the Author Rachel Warren is a contributing Motley Fool stock market analyst covering pharmaceuticals, biotechnology, medical devices, information technology, and consumer goods
4,5 In 2011 to 2012 in the United States, approximately 35% of adults, or nearly 80 million adults, lived with obesity
Beyond its primary indication for type 2 diabetes treatment, Efsubaglutide Alfa has also demonstrated cardiovascular benefits and potential efficacy in addressing other metabolic disorders such as obesity
[2] Tirzepatide is a dual GIP and GLP-1 receptor agonist, PubMed
doi: 10.18632/aging.203231